胸腺素α_1联合动脉导管化疗药物灌注栓塞治疗原发性肝癌的疗效观察

Therapeutic efficacy of thymosin α1 combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer

目的观察胸腺素α1联合动脉导管化疗药物灌注栓塞（TACE）治疗原发性肝癌的临床疗效,分析其安全性。方法将2007年8月~2011年5月期间本院收治的200例原发性肝癌患者分为2组,治疗组接受胸腺素α1联合TACE治疗,对照组仅接受TACE治疗,观察并对比2组疗效及安全性。结果治疗组在肿瘤反应疗效、肿瘤标志物降低和细胞免疫功能调节方面明显优于对照组。治疗组出现毒副作用比例及程度较对照组更低。结论胸腺素α1联合TACE治疗原发性肝癌疗效显著,安全可靠,是原发性肝癌的理想非手术治疗方法。

Objective To observe the clinical efficacy of thymosin α1 combined with transcatheter arterial chemoembolization（TACE） in the treatment of primary liver cancer and analyze its safety.Methods A total of 200 patients with primary liver cancer who were admitted to our hospital from August 2007 to May 2011 were divided into two groups.The treatment group received thymosin α1 combined with TACE,while the control group only received TACE treatment.After treatment,the efficacy and safety of the two groups were observed and compared.Results The efficacy of the treatment group was better than that of the control group in tumor response,tumor markers reduction and cellular immune function regulation.The proportion of patients with side effects of the treatment group was lower than that of the control group.Conclusion Thymosin α1 combined with TACE is effective,safe and reliable for primary liver cancer.It is an ideal non-surgical treatment for primary liver cancer.